AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014
Feb 25, 2014
31868_dirs_2014-02-25_9bc110e8-9263-4abb-b455-bed6dd12ea45.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-02-24
Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-24 | Common Stock | M | 23179 | $4.30 | Acquired | 229809 | Direct |
| 2014-02-24 | Common Stock | F | 8170 | $12.20 | Disposed | 221639 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-02-24 | Emp. Stock Option (Right to Buy) | $4.30 | M | 23179 | Disposed | 2015-05-11 | Common Stock (23179) | Direct |
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20